[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAnxJVRJEf_oLBR0eJWjgV9t01D7wmXrX9GyZYOlhDNc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Children's Hospital of Philadelphia",[4],480,false,104,21,3013856,25,368,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Cystic Fibrosis",13,{"name":18,"count":19},"Depression",9,{"name":21,"count":19},"Asthma",{"name":23,"count":24},"Cancer",8,{"name":26,"count":27},"Bronchopulmonary Dysplasia",7,{"name":29,"count":27},"Parent-Child Relations",{"name":31,"count":27},"Obesity",{"name":33,"count":27},"Leukemia",[35,40,45,50,55,60,65,70,74,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT01050855","Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders","2024-07","RIC: Distal Campath",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04901975","Fibrosis and the Fontan","2026-06-30","Spironolactone",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT01852448","Genetics of Insulin and Incretins in Cystic Fibrosis","2026-07","Blood or Saliva Sample Collection",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06693752","CEUS Evaluation of Hydrocephalus in Neonates and Infants","2026-08-01","Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06440408","Calculating Wall Shear Stress in Infant Pulmonary Veins","2026-09","Ferumoxytol",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05783323","Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","2026-10-01","Larotrectinib monotherapy",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT03473249","Effectiveness of Contrast-Enhanced Ultrasound","2026-12","Contrast-Enhanced Ultrasound using Lumason",{"nctId":71,"briefTitle":72,"date":68,"intervention":73},"NCT05553041","18F-Fluciclovine PET-MRI in High-grade Glioma","18F-Fluciclovine PET-MRI",{"nctId":75,"briefTitle":76,"date":68,"intervention":77},"NCT05555550","Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG","18F-Fluciclovine",{"nctId":79,"briefTitle":80,"date":68,"intervention":81},"NCT03301038","Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria","Rifampin",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,117,143,171,194,217,245,270,293,318,336,354,380,410,431,455,482,503,530,557,582,603,629,654,682,702,745,774,792,810,835,853,878,904,922,947,965,991,1020,1049,1067,1085,1103,1130,1148,1172,1190,1213,1237,1302,1346,1390,1412,1434,1464,1482,1508,1526,1544,1570,1588,1606,1624,1649,1702,1735,1753,1771,1789,1814,1838,1856,1879,1904,1931,1949,1974,1999,2024,2042,2067,2093,2111,2139,2166,2196,2214,2238,2256,2281,2306,2334,2352,2370,2398,2416,2434,2452,2470,2488,2512,2536,2560,2585,2609,2633,2659,2677,2701,2725,2749,2774,2797,2822,2845,2868,2892,2935,2967,2996,3019,3042,3067,3085,3109,3133,3155,3179,3202,3227,3251,3277,3304,3322,3345,3369,3394],{"intervention":69,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":115},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":68},[104],{"nctId":66,"briefTitle":67,"status":105,"phases":106,"primaryCompletion":68,"completion":68,"start":107,"enrollment":108,"conditions":109,"interventions":114},"ACTIVE_NOT_RECRUITING",[87],"2018-05-09",120,[110,111,112,113],"Abdominal Injuries","Physical Abuse","Accidental Fall","Motor Vehicle Injury",[69],{"trials":116,"activeCount":95},[],{"intervention":118,"totalTrials":91,"cells":119},"Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]",{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":141},{"trials":121,"activeCount":95},[],{"trials":123,"activeCount":95},[],{"trials":125,"activeCount":95},[],{"trials":127,"activeCount":95},[],{"trials":129,"activeCount":91,"soonestReadout":135},[130],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT03490929","CEUS for Blunt Abdominal Trauma in Children","RECRUITING",[87],"2026-12-31","2018-06-01",146,[139],"Trauma Abdomen",[118],{"trials":142,"activeCount":95},[],{"intervention":144,"totalTrials":91,"cells":145},"Trametinib",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":147,"activeCount":95},[],{"trials":149,"activeCount":95},[],{"trials":151,"activeCount":91,"soonestReadout":156},[152],{"nctId":153,"briefTitle":154,"status":105,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":164},"NCT07549646","24VA021; VATCH Trametinib for Ras\u002FMAPK Pathway VAs",[85],"2029-08-27","2030-08-27","2025-08-27",45,[161,162,163],"Ras\u002FMAPK Pathway Vascular Anomalies","Vascular Anomalies","Vascular Anomaly",[144],{"trials":166,"activeCount":95},[],{"trials":168,"activeCount":95},[],{"trials":170,"activeCount":95},[],{"intervention":64,"totalTrials":91,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":174,"activeCount":95},[],{"trials":176,"activeCount":95},[],{"trials":178,"activeCount":91,"soonestReadout":63},[179],{"nctId":61,"briefTitle":62,"status":133,"phases":180,"primaryCompletion":63,"completion":181,"start":182,"enrollment":16,"conditions":183,"interventions":187},[85],"2027-10-01","2024-02-14",[184,185,23,186],"Differentiated Thyroid Cancer","Pediatric Cancer","Cancer, Thyroid",[64],{"trials":189,"activeCount":95},[],{"trials":191,"activeCount":95},[],{"trials":193,"activeCount":95},[],{"intervention":54,"totalTrials":91,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":197,"activeCount":95},[],{"trials":199,"activeCount":95},[],{"trials":201,"activeCount":91,"soonestReadout":53},[202],{"nctId":51,"briefTitle":52,"status":133,"phases":203,"primaryCompletion":53,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":210},[85],"2027-08-01","2026-05-05",20,[208,209],"Hydrocephalus in Infants","Hydrocephalus Acquired",[54],{"trials":212,"activeCount":95},[],{"trials":214,"activeCount":95},[],{"trials":216,"activeCount":95},[],{"intervention":218,"totalTrials":91,"cells":219},"Lurbinectedin",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":221,"activeCount":95},[],{"trials":223,"activeCount":95},[],{"trials":225,"activeCount":91,"soonestReadout":230},[226],{"nctId":227,"briefTitle":228,"status":133,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":238},"NCT05918640","Lurbinectedin in FET-Fused Tumors",[84,85],"2027-07-30","2028-07-30","2023-07-27",63,[235,236,185,237],"Ewing Sarcoma","Desmoplastic Small Round Cell Tumor","Undifferentiated Sarcoma",[218],{"trials":240,"activeCount":95},[],{"trials":242,"activeCount":95},[],{"trials":244,"activeCount":95},[],{"intervention":246,"totalTrials":91,"cells":247},"ALS20",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":95},[],{"trials":253,"activeCount":91,"soonestReadout":258},[254],{"nctId":255,"briefTitle":256,"status":133,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT06364774","ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia",[84,85],"2027-12-31","2025-04-14",12,[262],"Beta-Thalassemia",[246],{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":95},[],{"intervention":271,"totalTrials":91,"cells":272},"alpelisib",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":274,"activeCount":95},[],{"trials":276,"activeCount":95},[],{"trials":278,"activeCount":91,"soonestReadout":156},[279],{"nctId":280,"briefTitle":281,"status":105,"phases":282,"primaryCompletion":156,"completion":157,"start":158,"enrollment":283,"conditions":284,"interventions":286},"NCT07543822","24VA022; VATCH Alpelisib for TIE2\u002FPIK3CA Pathway VAs",[85],61,[162,163,285],"TIE2\u002FPIK3CA Pathway Driven Vascular Anomalies",[271],{"trials":288,"activeCount":95},[],{"trials":290,"activeCount":95},[],{"trials":292,"activeCount":95},[],{"intervention":39,"totalTrials":91,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":296,"activeCount":95},[],{"trials":298,"activeCount":95},[],{"trials":300,"activeCount":91,"soonestReadout":38},[301],{"nctId":36,"briefTitle":37,"status":105,"phases":302,"primaryCompletion":38,"completion":68,"start":303,"enrollment":304,"conditions":305,"interventions":309},[85],"2008-01",75,[306,307,308],"Non Malignant Diseases","Immunodeficiencies","Hemoglobinopathies",[39,310,311],"RIC:Intermediate Campath","RIC: Mini Busulfan",{"trials":313,"activeCount":95},[],{"trials":315,"activeCount":95},[],{"trials":317,"activeCount":95},[],{"intervention":310,"totalTrials":91,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":321,"activeCount":95},[],{"trials":323,"activeCount":95},[],{"trials":325,"activeCount":91,"soonestReadout":38},[326],{"nctId":36,"briefTitle":37,"status":105,"phases":327,"primaryCompletion":38,"completion":68,"start":303,"enrollment":304,"conditions":328,"interventions":329},[85],[306,307,308],[39,310,311],{"trials":331,"activeCount":95},[],{"trials":333,"activeCount":95},[],{"trials":335,"activeCount":95},[],{"intervention":311,"totalTrials":91,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":339,"activeCount":95},[],{"trials":341,"activeCount":95},[],{"trials":343,"activeCount":91,"soonestReadout":38},[344],{"nctId":36,"briefTitle":37,"status":105,"phases":345,"primaryCompletion":38,"completion":68,"start":303,"enrollment":304,"conditions":346,"interventions":347},[85],[306,307,308],[39,310,311],{"trials":349,"activeCount":95},[],{"trials":351,"activeCount":95},[],{"trials":353,"activeCount":95},[],{"intervention":355,"totalTrials":91,"cells":356},"Red cell units that are genotype matched at the RHD and RHCE loci",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":358,"activeCount":95},[],{"trials":360,"activeCount":95},[],{"trials":362,"activeCount":91,"soonestReadout":367},[363],{"nctId":364,"briefTitle":365,"status":133,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":373},"NCT04156893","RH Genotype Matched RBC Transfusions",[84,85],"2029-04","2029-10","2020-01-30",35,[372],"Sickle Cells Disease",[355],{"trials":375,"activeCount":95},[],{"trials":377,"activeCount":95},[],{"trials":379,"activeCount":95},[],{"intervention":381,"totalTrials":91,"cells":382},"CART19",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":404,"PHASE4":406,"NA":408},{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":91,"soonestReadout":393},[389],{"nctId":390,"briefTitle":391,"status":133,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":403},"NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus",[84,85],"2030-02-28","2025-05-06",24,[397,398,399,381,400,401,402],"SLE","Systemic Lupus Erythematosus (SLE)","CAR T Cell","Cell Therapy","Lupus","Lupus Nephritis (LN)",[381],{"trials":405,"activeCount":95},[],{"trials":407,"activeCount":95},[],{"trials":409,"activeCount":95},[],{"intervention":44,"totalTrials":91,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":413,"activeCount":95},[],{"trials":415,"activeCount":95},[],{"trials":417,"activeCount":91,"soonestReadout":43},[418],{"nctId":41,"briefTitle":42,"status":133,"phases":419,"primaryCompletion":43,"completion":43,"start":420,"enrollment":421,"conditions":422,"interventions":424},[84,85],"2021-02-11",145,[423],"Single-ventricle",[44],{"trials":426,"activeCount":95},[],{"trials":428,"activeCount":95},[],{"trials":430,"activeCount":95},[],{"intervention":432,"totalTrials":91,"cells":433},"Selpercatinib Monotherapy",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":435,"activeCount":95},[],{"trials":437,"activeCount":95},[],{"trials":439,"activeCount":91,"soonestReadout":444},[440],{"nctId":441,"briefTitle":442,"status":133,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":16,"conditions":447,"interventions":448},"NCT06458036","Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)",[85],"2030-11-01","2031-11-01","2024-07-29",[184,185,23,186],[432],{"trials":450,"activeCount":95},[],{"trials":452,"activeCount":95},[],{"trials":454,"activeCount":95},[],{"intervention":81,"totalTrials":91,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":458,"activeCount":95},[],{"trials":460,"activeCount":95},[],{"trials":462,"activeCount":91,"soonestReadout":68},[463],{"nctId":79,"briefTitle":80,"status":133,"phases":464,"primaryCompletion":68,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":475},[85],"2030-12","2018-07-25",60,[469,470,471,472,473,474],"Idiopathic Infantile Hypercalcaemia - Severe Form","Genetic Disease","Hypercalcemia, Idiopathic, of Infancy","Hypercalciuric Hypercalcemia","Idiopathic Infantile Hypercalcemia - Mild Form","Hypercalciuria",[81],{"trials":477,"activeCount":95},[],{"trials":479,"activeCount":95},[],{"trials":481,"activeCount":95},[],{"intervention":59,"totalTrials":91,"cells":483},{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":485,"activeCount":95},[],{"trials":487,"activeCount":91,"soonestReadout":58},[488],{"nctId":56,"briefTitle":57,"status":133,"phases":489,"primaryCompletion":58,"completion":490,"start":491,"enrollment":206,"conditions":492,"interventions":494},[84],"2027-03","2024-09-30",[493],"Pulmonary Vein Stenosis",[59],{"trials":496,"activeCount":95},[],{"trials":498,"activeCount":95},[],{"trials":500,"activeCount":95},[],{"trials":502,"activeCount":95},[],{"intervention":504,"totalTrials":91,"cells":505},"Lumason® contrast agent",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":507,"activeCount":95},[],{"trials":509,"activeCount":91,"soonestReadout":514},[510],{"nctId":511,"briefTitle":512,"status":133,"phases":513,"primaryCompletion":514,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":521},"NCT05569122","Applying pGz in Mitochondrial Disease",[84],"2027-09","2028-09","2023-03-22",90,[519,520],"Mitochondrial Myopathies","Mitochondrial Diseases",[504],{"trials":523,"activeCount":95},[],{"trials":525,"activeCount":95},[],{"trials":527,"activeCount":95},[],{"trials":529,"activeCount":95},[],{"intervention":531,"totalTrials":91,"cells":532},"Cabozantinib",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":534,"activeCount":95},[],{"trials":536,"activeCount":91,"soonestReadout":541},[537],{"nctId":538,"briefTitle":539,"status":133,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":548},"NCT06156410","Cabozantinib With Ifosfamide in Relapsed\u002FRefractory Sarcomas",[84],"2027-11","2028-11","2023-10-24",30,[235,546,547],"Osteosarcoma","Sarcomas",[531],{"trials":550,"activeCount":95},[],{"trials":552,"activeCount":95},[],{"trials":554,"activeCount":95},[],{"trials":556,"activeCount":95},[],{"intervention":73,"totalTrials":91,"cells":558},{"EARLY_PHASE1":559,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":560,"activeCount":91,"soonestReadout":68},[561],{"nctId":71,"briefTitle":72,"status":133,"phases":562,"primaryCompletion":68,"completion":563,"start":564,"enrollment":544,"conditions":565,"interventions":571},[83],"2027-12","2024-08-07",[566,567,568,569,570],"Glioma","High Grade Glioma","Glioma, Malignant","Glioma Intracranial","Diffuse Glioma",[73],{"trials":573,"activeCount":95},[],{"trials":575,"activeCount":95},[],{"trials":577,"activeCount":95},[],{"trials":579,"activeCount":95},[],{"trials":581,"activeCount":95},[],{"intervention":77,"totalTrials":91,"cells":583},{"EARLY_PHASE1":584,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":585,"activeCount":91,"soonestReadout":68},[586],{"nctId":75,"briefTitle":76,"status":133,"phases":587,"primaryCompletion":68,"completion":514,"start":588,"enrollment":544,"conditions":589,"interventions":592},[83],"2026-07-29",[566,590,591,568,569],"Low-grade Glioma","Low Grade Glioma of Brain",[77],{"trials":594,"activeCount":95},[],{"trials":596,"activeCount":95},[],{"trials":598,"activeCount":95},[],{"trials":600,"activeCount":95},[],{"trials":602,"activeCount":95},[],{"intervention":604,"totalTrials":91,"cells":605},"Lumason",{"EARLY_PHASE1":606,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":607,"activeCount":91,"soonestReadout":612},[608],{"nctId":609,"briefTitle":610,"status":133,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT03107520","Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH",[83],"2027-04","2030-04","2017-05-22",125,[617],"Developmental Dysplasia of the Hip",[604],{"trials":620,"activeCount":95},[],{"trials":622,"activeCount":95},[],{"trials":624,"activeCount":95},[],{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":95},[],{"intervention":630,"totalTrials":91,"cells":631},"BK-virus specific CTLs",{"EARLY_PHASE1":632,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":633,"activeCount":91,"soonestReadout":638},[634],{"nctId":635,"briefTitle":636,"status":133,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":206,"conditions":641,"interventions":643},"NCT04293042","Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients",[83],"2027-01-30","2028-12-30","2019-10-07",[642],"BK Polyomavirus",[630],{"trials":645,"activeCount":95},[],{"trials":647,"activeCount":95},[],{"trials":649,"activeCount":95},[],{"trials":651,"activeCount":95},[],{"trials":653,"activeCount":95},[],{"intervention":655,"totalTrials":91,"cells":656},"Transplant of stem cells with CD3+\u002FCD19+ depletion",{"EARLY_PHASE1":657,"PHASE1":672,"PHASE2":674,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":658,"activeCount":91,"soonestReadout":663},[659],{"nctId":660,"briefTitle":661,"status":133,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":671},"NCT02356653","Expanded Access Protocol Using CD3+\u002FCD19+ Depleted PBSC",[83],"2027-01","2030-01","2013-12",100,[33,668,669,307,670],"Inborn Errors of Metabolism","Bone Marrow Failure Syndromes","Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome",[655],{"trials":673,"activeCount":95},[],{"trials":675,"activeCount":95},[],{"trials":677,"activeCount":95},[],{"trials":679,"activeCount":95},[],{"trials":681,"activeCount":95},[],{"intervention":49,"totalTrials":91,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":685,"activeCount":95},[],{"trials":687,"activeCount":95},[],{"trials":689,"activeCount":95},[],{"trials":691,"activeCount":95},[],{"trials":693,"activeCount":95},[],{"trials":695,"activeCount":91,"soonestReadout":48},[696],{"nctId":46,"briefTitle":47,"status":133,"phases":697,"primaryCompletion":48,"completion":48,"start":698,"enrollment":699,"conditions":700,"interventions":701},[],"2013-05",550,[15],[49],{"intervention":703,"totalTrials":704,"cells":705},"Dexmedetomidine",2,{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":743},{"trials":707,"activeCount":95},[],{"trials":709,"activeCount":95},[710],{"nctId":711,"briefTitle":712,"status":713,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT03417999","Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease","TERMINATED",[84],"2021-10-12","2018-06-14",28,[703,719],"Congenital Heart Disease",[703],{"trials":722,"activeCount":95},[],{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[727],{"nctId":728,"briefTitle":729,"status":713,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":370,"conditions":733,"interventions":739},"NCT04528173","Opioid-Free Anesthetic for Tonsillectomy",[87],"2023-08-22","2020-07-22",[734,735,736,737,738],"Anesthesia","Opioid Use","Tonsillitis","Sleep Disorder","Surgery",[740,703,741,742],"Ketorolac","Morphine","Fentanyl",{"trials":744,"activeCount":95},[],{"intervention":742,"totalTrials":704,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":766,"NA":772},{"trials":748,"activeCount":95},[],{"trials":750,"activeCount":95},[],{"trials":752,"activeCount":95},[],{"trials":754,"activeCount":95},[755],{"nctId":756,"briefTitle":757,"status":758,"phases":759,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":765},"NCT00286143","Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates","COMPLETED",[86],"2007-12","2005-02",32,[764],"Congenital Cystic Adenomatoid Malformation",[742],{"trials":767,"activeCount":95},[768],{"nctId":728,"briefTitle":729,"status":713,"phases":769,"primaryCompletion":731,"completion":731,"start":732,"enrollment":370,"conditions":770,"interventions":771},[87],[734,735,736,737,738],[740,703,741,742],{"trials":773,"activeCount":95},[],{"intervention":740,"totalTrials":91,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":790},{"trials":777,"activeCount":95},[],{"trials":779,"activeCount":95},[],{"trials":781,"activeCount":95},[],{"trials":783,"activeCount":95},[],{"trials":785,"activeCount":95},[786],{"nctId":728,"briefTitle":729,"status":713,"phases":787,"primaryCompletion":731,"completion":731,"start":732,"enrollment":370,"conditions":788,"interventions":789},[87],[734,735,736,737,738],[740,703,741,742],{"trials":791,"activeCount":95},[],{"intervention":741,"totalTrials":91,"cells":793},{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":808},{"trials":795,"activeCount":95},[],{"trials":797,"activeCount":95},[],{"trials":799,"activeCount":95},[],{"trials":801,"activeCount":95},[],{"trials":803,"activeCount":95},[804],{"nctId":728,"briefTitle":729,"status":713,"phases":805,"primaryCompletion":731,"completion":731,"start":732,"enrollment":370,"conditions":806,"interventions":807},[87],[734,735,736,737,738],[740,703,741,742],{"trials":809,"activeCount":95},[],{"intervention":811,"totalTrials":91,"cells":812},"Combination of pimecrolimus and fluticasone",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":833},{"trials":814,"activeCount":95},[],{"trials":816,"activeCount":95},[],{"trials":818,"activeCount":95},[],{"trials":820,"activeCount":95},[],{"trials":822,"activeCount":95},[823],{"nctId":824,"briefTitle":825,"status":758,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":517,"conditions":829,"interventions":831},"NCT00119158","Combination Therapy for Atopic Dermatitis",[87],"2005-06","2004-10",[830],"Atopic Dermatitis",[811,832],"pimecrolimus",{"trials":834,"activeCount":95},[],{"intervention":832,"totalTrials":91,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":851},{"trials":838,"activeCount":95},[],{"trials":840,"activeCount":95},[],{"trials":842,"activeCount":95},[],{"trials":844,"activeCount":95},[],{"trials":846,"activeCount":95},[847],{"nctId":824,"briefTitle":825,"status":758,"phases":848,"primaryCompletion":827,"completion":827,"start":828,"enrollment":517,"conditions":849,"interventions":850},[87],[830],[811,832],{"trials":852,"activeCount":95},[],{"intervention":854,"totalTrials":91,"cells":855},"polyethylene glycol, senna",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":876},{"trials":857,"activeCount":95},[],{"trials":859,"activeCount":95},[],{"trials":861,"activeCount":95},[],{"trials":863,"activeCount":95},[],{"trials":865,"activeCount":95},[866],{"nctId":867,"briefTitle":868,"status":713,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":875},"NCT01140295","Bowel Preparation for Colonoscopy in Children",[87],"2011-05","2010-09",33,[874],"Colonoscopy Preparation",[854],{"trials":877,"activeCount":95},[],{"intervention":879,"totalTrials":91,"cells":880},"Paracervical Nerve Block",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":902},{"trials":882,"activeCount":95},[],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"trials":888,"activeCount":95},[],{"trials":890,"activeCount":95},[891],{"nctId":892,"briefTitle":893,"status":758,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT02352714","Study of Pain Control With Hormonal IUS Insertion",[87],"2016-07","2015-01",98,[899],"Pain",[879,901],"Sham Paracervical Block",{"trials":903,"activeCount":95},[],{"intervention":901,"totalTrials":91,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":95},[],{"trials":909,"activeCount":95},[],{"trials":911,"activeCount":95},[],{"trials":913,"activeCount":95},[],{"trials":915,"activeCount":95},[916],{"nctId":892,"briefTitle":893,"status":758,"phases":917,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":918,"interventions":919},[87],[899],[879,901],{"trials":921,"activeCount":95},[],{"intervention":923,"totalTrials":91,"cells":924},"Racemic albuterol",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":945},{"trials":926,"activeCount":95},[],{"trials":928,"activeCount":95},[],{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":95},[935],{"nctId":936,"briefTitle":937,"status":758,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT00124176","Continuous Levalbuterol for Treatment of Status Asthmaticus in Children",[87],"2006-02","2004-04",81,[21],[923,944],"Levalbuterol",{"trials":946,"activeCount":95},[],{"intervention":944,"totalTrials":91,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":963},{"trials":950,"activeCount":95},[],{"trials":952,"activeCount":95},[],{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[959],{"nctId":936,"briefTitle":937,"status":758,"phases":960,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":961,"interventions":962},[87],[21],[923,944],{"trials":964,"activeCount":95},[],{"intervention":966,"totalTrials":91,"cells":967},"Ketamine",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":989},{"trials":969,"activeCount":95},[],{"trials":971,"activeCount":95},[],{"trials":973,"activeCount":95},[],{"trials":975,"activeCount":95},[],{"trials":977,"activeCount":95},[978],{"nctId":979,"briefTitle":980,"status":713,"phases":981,"primaryCompletion":982,"completion":983,"start":984,"enrollment":985,"conditions":986,"interventions":988},"NCT00252122","Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease",[87],"2005-11","2007-01","2004-06",3,[987],"Sickle Cell Disease",[966],{"trials":990,"activeCount":95},[],{"intervention":992,"totalTrials":91,"cells":993},"Baloxavir Marboxil",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1018},{"trials":995,"activeCount":95},[],{"trials":997,"activeCount":95},[],{"trials":999,"activeCount":95},[],{"trials":1001,"activeCount":95},[],{"trials":1003,"activeCount":95},[1004],{"nctId":1005,"briefTitle":1006,"status":758,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1017},"NCT06161454","Xofluza-Wearables Feasibility-Study",[87],"2025-04-30","2023-12-14",498,[1012,1013,1014,1015,1016],"Infection, Coronavirus","Infections","Influenza","Transplant","Infection Viral",[992],{"trials":1019,"activeCount":95},[],{"intervention":1021,"totalTrials":91,"cells":1022},"Budesonide inhalation suspension (0.5 mg\u002F2mL) 2mg, albuterol (5mg\u002FmL) 7.5 or 10mg",{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1029,"PHASE4":1031,"NA":1047},{"trials":1024,"activeCount":95},[],{"trials":1026,"activeCount":95},[],{"trials":1028,"activeCount":95},[],{"trials":1030,"activeCount":95},[],{"trials":1032,"activeCount":95},[1033],{"nctId":1034,"briefTitle":1035,"status":758,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1043},"NCT00393367","Budesonide Inhalation Suspension for Acute Asthma in Children",[87],"2007-11","2006-12",179,[21,1041,1042],"Acute Asthma","Reactive Airway Exacerbation",[1021,1044,1045,1046],"Prednisolone, prednisone, or methylprednisolone","Albuterol, ipratropium bromide","Ipratropium bromide",{"trials":1048,"activeCount":95},[],{"intervention":1044,"totalTrials":91,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1065},{"trials":1052,"activeCount":95},[],{"trials":1054,"activeCount":95},[],{"trials":1056,"activeCount":95},[],{"trials":1058,"activeCount":95},[],{"trials":1060,"activeCount":95},[1061],{"nctId":1034,"briefTitle":1035,"status":758,"phases":1062,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1063,"interventions":1064},[87],[21,1041,1042],[1021,1044,1045,1046],{"trials":1066,"activeCount":95},[],{"intervention":1045,"totalTrials":91,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1083},{"trials":1070,"activeCount":95},[],{"trials":1072,"activeCount":95},[],{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"trials":1078,"activeCount":95},[1079],{"nctId":1034,"briefTitle":1035,"status":758,"phases":1080,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1081,"interventions":1082},[87],[21,1041,1042],[1021,1044,1045,1046],{"trials":1084,"activeCount":95},[],{"intervention":1046,"totalTrials":91,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1101},{"trials":1088,"activeCount":95},[],{"trials":1090,"activeCount":95},[],{"trials":1092,"activeCount":95},[],{"trials":1094,"activeCount":95},[],{"trials":1096,"activeCount":95},[1097],{"nctId":1034,"briefTitle":1035,"status":758,"phases":1098,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1099,"interventions":1100},[87],[21,1041,1042],[1021,1044,1045,1046],{"trials":1102,"activeCount":95},[],{"intervention":1104,"totalTrials":91,"cells":1105},"Nebulized 3% saline",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1128},{"trials":1107,"activeCount":95},[],{"trials":1109,"activeCount":95},[],{"trials":1111,"activeCount":95},[],{"trials":1113,"activeCount":95},[],{"trials":1115,"activeCount":95},[1116],{"nctId":1117,"briefTitle":1118,"status":758,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1126},"NCT01247064","Hypertonic Saline for Acute Bronchiolitis",[87],"2011-12","2010-10",62,[1124,1125],"Bronchiolitis, Viral","Saline Solution, Hypertonic",[1104,1127],"Nebulized 0.9% Normal Saline",{"trials":1129,"activeCount":95},[],{"intervention":1127,"totalTrials":91,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1146},{"trials":1133,"activeCount":95},[],{"trials":1135,"activeCount":95},[],{"trials":1137,"activeCount":95},[],{"trials":1139,"activeCount":95},[],{"trials":1141,"activeCount":95},[1142],{"nctId":1117,"briefTitle":1118,"status":758,"phases":1143,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1122,"conditions":1144,"interventions":1145},[87],[1124,1125],[1104,1127],{"trials":1147,"activeCount":95},[],{"intervention":1149,"totalTrials":91,"cells":1150},"Prednisolone high dose",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1170},{"trials":1152,"activeCount":95},[],{"trials":1154,"activeCount":95},[],{"trials":1156,"activeCount":95},[],{"trials":1158,"activeCount":95},[],{"trials":1160,"activeCount":95},[1161],{"nctId":1162,"briefTitle":1163,"status":758,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":939,"enrollment":1166,"conditions":1167,"interventions":1168},"NCT00257933","Oral Prednisolone Dosing in Children Hospitalized With Asthma",[87],"2006-11",152,[21],[1149,1169],"Prednisolone lower dose",{"trials":1171,"activeCount":95},[],{"intervention":1169,"totalTrials":91,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1188},{"trials":1175,"activeCount":95},[],{"trials":1177,"activeCount":95},[],{"trials":1179,"activeCount":95},[],{"trials":1181,"activeCount":95},[],{"trials":1183,"activeCount":95},[1184],{"nctId":1162,"briefTitle":1163,"status":758,"phases":1185,"primaryCompletion":1165,"completion":1165,"start":939,"enrollment":1166,"conditions":1186,"interventions":1187},[87],[21],[1149,1169],{"trials":1189,"activeCount":95},[],{"intervention":1191,"totalTrials":91,"cells":1192},"OROS-methylphenidate",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1211},{"trials":1194,"activeCount":95},[],{"trials":1196,"activeCount":95},[],{"trials":1198,"activeCount":95},[],{"trials":1200,"activeCount":95},[],{"trials":1202,"activeCount":95},[1203],{"nctId":1204,"briefTitle":1205,"status":758,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":984,"enrollment":544,"conditions":1208,"interventions":1210},"NCT00530257","Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory",[87],"2008-06",[1209],"Attention Deficit Hyperactivity Disorder",[1191],{"trials":1212,"activeCount":95},[],{"intervention":1214,"totalTrials":91,"cells":1215},"Dupilumab",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1235},{"trials":1217,"activeCount":95},[],{"trials":1219,"activeCount":95},[],{"trials":1221,"activeCount":95},[],{"trials":1223,"activeCount":95},[],{"trials":1225,"activeCount":95},[1226],{"nctId":1227,"briefTitle":1228,"status":758,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":9,"conditions":1232,"interventions":1234},"NCT05247866","Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis",[87],"2025-01-21","2022-06-16",[1233],"Eosinophilic Esophagitis",[1214],{"trials":1236,"activeCount":95},[],{"intervention":1238,"totalTrials":1239,"cells":1240},"Normal Saline",4,{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1258,"PHASE3":1271,"PHASE4":1298,"NA":1300},{"trials":1242,"activeCount":95},[],{"trials":1244,"activeCount":95},[1245],{"nctId":1246,"briefTitle":1247,"status":758,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT03340805","Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study",[84],"2018-08-31","2019-01-15","2018-01-24",50,[1254],"Shock, Septic",[1256,1257],"Lactated Ringer","Normal saline",{"trials":1259,"activeCount":95},[1260],{"nctId":1261,"briefTitle":1262,"status":758,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":871,"enrollment":1266,"conditions":1267,"interventions":1269},"NCT01285713","IV Glucose for Dehydration Treatment",[85],"2011-08","2012-03",83,[1268],"Dehydration",[1270,1238],"5% Dextrose",{"trials":1272,"activeCount":95},[1273,1286],{"nctId":1274,"briefTitle":1275,"status":758,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1284},"NCT04102371","Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis",[86],"2025-12-01","2026-01-31","2020-08-25",9041,[1282,1283],"Shock","Septic",[1256,1238,1285],"Plasma-lyte",{"nctId":1287,"briefTitle":1288,"status":758,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":233,"conditions":1292,"interventions":1295},"NCT03526874","Occipital Blocks for Acute Migraine",[86],"2023-03-10","2019-04-03",[1293,1294],"Chronic Migraine, Headache","Episodic Migraine",[1296,1297,1238],"Lidocaine 4% Topical Application Cream [LMX 4]","Lidocaine Hydrochloride 2 mg\u002FmL Injectable Solution",{"trials":1299,"activeCount":95},[],{"trials":1301,"activeCount":95},[],{"intervention":1303,"totalTrials":985,"cells":1304},"Sulfur hexafluoride lipid-type A microspheres",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1342,"NA":1344},{"trials":1306,"activeCount":95},[],{"trials":1308,"activeCount":95},[],{"trials":1310,"activeCount":95},[],{"trials":1312,"activeCount":95},[1313,1323,1333],{"nctId":1314,"briefTitle":1315,"status":713,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":91,"conditions":1319,"interventions":1322},"NCT03549507","CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis",[86],"2024-05-07","2020-11-04",[1320,1321],"Necrotizing Enterocolitis of Newborn","Bowel Ischemic",[1303],{"nctId":1324,"briefTitle":1325,"status":758,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":1239,"conditions":1329,"interventions":1332},"NCT04640038","Contrast Enhanced Ultrasound in COVID-19",[86],"2021-09-17","2020-12-18",[1330,1331],"Covid19","Multisystem Inflammatory Syndrome in Children (MIS-C)",[1303],{"nctId":1334,"briefTitle":1335,"status":758,"phases":1336,"primaryCompletion":1317,"completion":1317,"start":1337,"enrollment":91,"conditions":1338,"interventions":1341},"NCT03549520","CEUS Evaluation of Hypoxic Ischemic Injury",[86],"2020-12-01",[1339,1340],"Hypoxic-Ischemic Encephalopathy","Brain Ischemia Hypoxia",[1303],{"trials":1343,"activeCount":95},[],{"trials":1345,"activeCount":95},[],{"intervention":1347,"totalTrials":704,"cells":1348},"Cyclophosphamide",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1369,"PHASE4":1386,"NA":1388},{"trials":1350,"activeCount":95},[],{"trials":1352,"activeCount":95},[],{"trials":1354,"activeCount":95},[1355],{"nctId":1356,"briefTitle":1357,"status":713,"phases":1358,"primaryCompletion":870,"completion":870,"start":1359,"enrollment":544,"conditions":1360,"interventions":1364},"NCT00031590","Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma",[85],"2001-04",[1361,1362,1363],"Brain Tumors","Central Nervous System Tumors","Medulloblastoma",[1365,1347,1366,1367,1368],"Cisplatin","Etoposide","Lomustine","Vincristine",{"trials":1370,"activeCount":95},[1371],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1374,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1379},"NCT00002961","Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia",[86],"2001-02","1995-10",43,[33],[1380,1381,1382,1383,1384,1385],"cyclophosphamide","cyclosporine","etoposide","methotrexate","Busulfan","Mesna",{"trials":1387,"activeCount":95},[],{"trials":1389,"activeCount":95},[],{"intervention":1366,"totalTrials":704,"cells":1391},{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1402,"PHASE4":1408,"NA":1410},{"trials":1393,"activeCount":95},[],{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[1398],{"nctId":1356,"briefTitle":1357,"status":713,"phases":1399,"primaryCompletion":870,"completion":870,"start":1359,"enrollment":544,"conditions":1400,"interventions":1401},[85],[1361,1362,1363],[1365,1347,1366,1367,1368],{"trials":1403,"activeCount":95},[1404],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1405,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1406,"interventions":1407},[86],[33],[1380,1381,1382,1383,1384,1385],{"trials":1409,"activeCount":95},[],{"trials":1411,"activeCount":95},[],{"intervention":1256,"totalTrials":704,"cells":1413},{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1422,"PHASE3":1424,"PHASE4":1430,"NA":1432},{"trials":1415,"activeCount":95},[],{"trials":1417,"activeCount":95},[1418],{"nctId":1246,"briefTitle":1247,"status":758,"phases":1419,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":1420,"interventions":1421},[84],[1254],[1256,1257],{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[1426],{"nctId":1274,"briefTitle":1275,"status":758,"phases":1427,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1428,"interventions":1429},[86],[1282,1283],[1256,1238,1285],{"trials":1431,"activeCount":95},[],{"trials":1433,"activeCount":95},[],{"intervention":1435,"totalTrials":704,"cells":1436},"Methotrexate",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1454,"PHASE4":1460,"NA":1462},{"trials":1438,"activeCount":95},[],{"trials":1440,"activeCount":95},[],{"trials":1442,"activeCount":95},[1443],{"nctId":1444,"briefTitle":1445,"status":758,"phases":1446,"primaryCompletion":665,"completion":1447,"start":1375,"enrollment":1448,"conditions":1449,"interventions":1452},"NCT00030264","Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas",[85],"2016-03",23,[1450,1451],"Neurofibromatosis Type 1","Precancerous Condition",[1435,1453],"Vinblastine",{"trials":1455,"activeCount":95},[1456],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1457,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1458,"interventions":1459},[86],[33],[1380,1381,1382,1383,1384,1385],{"trials":1461,"activeCount":95},[],{"trials":1463,"activeCount":95},[],{"intervention":1285,"totalTrials":91,"cells":1465},{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1472,"PHASE4":1478,"NA":1480},{"trials":1467,"activeCount":95},[],{"trials":1469,"activeCount":95},[],{"trials":1471,"activeCount":95},[],{"trials":1473,"activeCount":95},[1474],{"nctId":1274,"briefTitle":1275,"status":758,"phases":1475,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1476,"interventions":1477},[86],[1282,1283],[1256,1238,1285],{"trials":1479,"activeCount":95},[],{"trials":1481,"activeCount":95},[],{"intervention":1483,"totalTrials":91,"cells":1484},"Intravenous Acetaminophen",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1504,"NA":1506},{"trials":1486,"activeCount":95},[],{"trials":1488,"activeCount":95},[],{"trials":1490,"activeCount":95},[],{"trials":1492,"activeCount":95},[1493],{"nctId":1494,"briefTitle":1495,"status":758,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1503},"NCT01394718","Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients",[86],"2014-06","2015-07","2011-07",67,[1502],"Pain, Postoperative",[1483],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[],{"intervention":1296,"totalTrials":91,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1522,"NA":1524},{"trials":1511,"activeCount":95},[],{"trials":1513,"activeCount":95},[],{"trials":1515,"activeCount":95},[],{"trials":1517,"activeCount":95},[1518],{"nctId":1287,"briefTitle":1288,"status":758,"phases":1519,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":233,"conditions":1520,"interventions":1521},[86],[1293,1294],[1296,1297,1238],{"trials":1523,"activeCount":95},[],{"trials":1525,"activeCount":95},[],{"intervention":1297,"totalTrials":91,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1540,"NA":1542},{"trials":1529,"activeCount":95},[],{"trials":1531,"activeCount":95},[],{"trials":1533,"activeCount":95},[],{"trials":1535,"activeCount":95},[1536],{"nctId":1287,"briefTitle":1288,"status":758,"phases":1537,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":233,"conditions":1538,"interventions":1539},[86],[1293,1294],[1296,1297,1238],{"trials":1541,"activeCount":95},[],{"trials":1543,"activeCount":95},[],{"intervention":1545,"totalTrials":91,"cells":1546},"Nasal Fluticasone",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1566,"NA":1568},{"trials":1548,"activeCount":95},[],{"trials":1550,"activeCount":95},[],{"trials":1552,"activeCount":95},[],{"trials":1554,"activeCount":95},[1555],{"nctId":1556,"briefTitle":1557,"status":758,"phases":1558,"primaryCompletion":1559,"completion":1560,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1565},"NCT02180672","Steroids for Pediatric Apnea Research in Kids",[86],"2019-12-30","2021-10-30","2014-09",211,[1564],"Obstructive Sleep Apnea Syndrome",[1545],{"trials":1567,"activeCount":95},[],{"trials":1569,"activeCount":95},[],{"intervention":1381,"totalTrials":91,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":95},[],{"trials":1575,"activeCount":95},[],{"trials":1577,"activeCount":95},[],{"trials":1579,"activeCount":95},[1580],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1581,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1582,"interventions":1583},[86],[33],[1380,1381,1382,1383,1384,1385],{"trials":1585,"activeCount":95},[],{"trials":1587,"activeCount":95},[],{"intervention":1384,"totalTrials":91,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":95},[],{"trials":1593,"activeCount":95},[],{"trials":1595,"activeCount":95},[],{"trials":1597,"activeCount":95},[1598],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1599,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1600,"interventions":1601},[86],[33],[1380,1381,1382,1383,1384,1385],{"trials":1603,"activeCount":95},[],{"trials":1605,"activeCount":95},[],{"intervention":1385,"totalTrials":91,"cells":1607},{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1614,"PHASE4":1620,"NA":1622},{"trials":1609,"activeCount":95},[],{"trials":1611,"activeCount":95},[],{"trials":1613,"activeCount":95},[],{"trials":1615,"activeCount":95},[1616],{"nctId":1372,"briefTitle":1373,"status":713,"phases":1617,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1618,"interventions":1619},[86],[33],[1380,1381,1382,1383,1384,1385],{"trials":1621,"activeCount":95},[],{"trials":1623,"activeCount":95},[],{"intervention":1625,"totalTrials":91,"cells":1626},"Nitric Oxide",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1633,"PHASE4":1645,"NA":1647},{"trials":1628,"activeCount":95},[],{"trials":1630,"activeCount":95},[],{"trials":1632,"activeCount":95},[],{"trials":1634,"activeCount":95},[1635],{"nctId":1636,"briefTitle":1637,"status":758,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1644},"NCT00240487","Nitric Oxide Administration for Acute Respiratory Distress Syndrome",[86],"2008-09","2000-09",52,[1643],"Acute Respiratory Distress Syndrome",[1625],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[],{"intervention":1650,"totalTrials":985,"cells":1651},"sirolimus",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1667,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1653,"activeCount":95},[],{"trials":1655,"activeCount":95},[1656],{"nctId":1657,"briefTitle":1658,"status":713,"phases":1659,"primaryCompletion":1660,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1666},"NCT00068302","Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma",[84],"2009-04","2013-07","2003-01",10,[33,1665],"Lymphoma",[1650],{"trials":1668,"activeCount":95},[1669,1685],{"nctId":1670,"briefTitle":1671,"status":758,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1038,"enrollment":544,"conditions":1674,"interventions":1684},"NCT00392951","Sirolimus for Autoimmune Disease of Blood Cells",[84,85],"2016-02",[1675,1676,1677,1678,1679,1680,1681,1682,1683],"Autoimmune Pancytopenia","Autoimmune Lymphoproliferative Syndrome (ALPS)","Evans Syndrome","Idiopathic Thrombocytopenic Purpura","Anemia, Hemolytic, Autoimmune","Autoimmune Neutropenia","Lupus Erythematosus, Systemic","Inflammatory Bowel Disease","Rheumatoid Arthritis",[1650],{"nctId":1686,"briefTitle":1687,"status":1688,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":95,"conditions":1692,"interventions":1694},"NCT02524639","Sirolimus for the Treatment of Hyperinsulinism","WITHDRAWN",[84,85],"2018-05-29","2015-08-12",[1693],"Hyperinsulinism",[1695],"Sirolimus",{"trials":1697,"activeCount":95},[],{"trials":1699,"activeCount":95},[],{"trials":1701,"activeCount":95},[],{"intervention":1703,"totalTrials":704,"cells":1704},"Sodium 4-Phenylbutyrate",{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1706,"activeCount":95},[],{"trials":1708,"activeCount":95},[],{"trials":1710,"activeCount":95},[1711,1720],{"nctId":1712,"briefTitle":1713,"status":758,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":260,"conditions":1717,"interventions":1718},"NCT00016744","Phenylbutyrate\u002FGenistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)",[84,85],"2005-10","2001-09",[15],[1703,1719],"Unconjugated Isoflavones 100",{"nctId":1721,"briefTitle":1722,"status":713,"phases":1723,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":19,"conditions":1726,"interventions":1727},"NCT00590538","Phenylbutyrate\u002FGenistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)",[84,85],"2008-12","2003-02",[15],[1703,1728],"Genistein",{"trials":1730,"activeCount":95},[],{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[],{"intervention":1365,"totalTrials":91,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1738,"activeCount":95},[],{"trials":1740,"activeCount":95},[],{"trials":1742,"activeCount":95},[1743],{"nctId":1356,"briefTitle":1357,"status":713,"phases":1744,"primaryCompletion":870,"completion":870,"start":1359,"enrollment":544,"conditions":1745,"interventions":1746},[85],[1361,1362,1363],[1365,1347,1366,1367,1368],{"trials":1748,"activeCount":95},[],{"trials":1750,"activeCount":95},[],{"trials":1752,"activeCount":95},[],{"intervention":1367,"totalTrials":91,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":95},[],{"trials":1758,"activeCount":95},[],{"trials":1760,"activeCount":95},[1761],{"nctId":1356,"briefTitle":1357,"status":713,"phases":1762,"primaryCompletion":870,"completion":870,"start":1359,"enrollment":544,"conditions":1763,"interventions":1764},[85],[1361,1362,1363],[1365,1347,1366,1367,1368],{"trials":1766,"activeCount":95},[],{"trials":1768,"activeCount":95},[],{"trials":1770,"activeCount":95},[],{"intervention":1368,"totalTrials":91,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":95},[],{"trials":1776,"activeCount":95},[],{"trials":1778,"activeCount":95},[1779],{"nctId":1356,"briefTitle":1357,"status":713,"phases":1780,"primaryCompletion":870,"completion":870,"start":1359,"enrollment":544,"conditions":1781,"interventions":1782},[85],[1361,1362,1363],[1365,1347,1366,1367,1368],{"trials":1784,"activeCount":95},[],{"trials":1786,"activeCount":95},[],{"trials":1788,"activeCount":95},[],{"intervention":1790,"totalTrials":91,"cells":1791},"Elamipretide",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1793,"activeCount":95},[],{"trials":1795,"activeCount":95},[],{"trials":1797,"activeCount":95},[1798],{"nctId":1799,"briefTitle":1800,"status":758,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":206,"conditions":1805,"interventions":1807},"NCT05168774","FRDA Investigator Initiated Study (IIS) With Elamipretide",[84,85],"2024-06-25","2024-07-25","2022-03-03",[1806],"Friedreich Ataxia",[1790],{"trials":1809,"activeCount":95},[],{"trials":1811,"activeCount":95},[],{"trials":1813,"activeCount":95},[],{"intervention":1815,"totalTrials":91,"cells":1816},"Atorvastatin",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1818,"activeCount":95},[],{"trials":1820,"activeCount":95},[],{"trials":1822,"activeCount":95},[1823],{"nctId":1824,"briefTitle":1825,"status":758,"phases":1826,"primaryCompletion":1499,"completion":1661,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT00529191","Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)",[85],"2007-07",40,[1830],"Type 1 Diabetes",[1815],{"trials":1833,"activeCount":95},[],{"trials":1835,"activeCount":95},[],{"trials":1837,"activeCount":95},[],{"intervention":1719,"totalTrials":91,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1841,"activeCount":95},[],{"trials":1843,"activeCount":95},[],{"trials":1845,"activeCount":95},[1846],{"nctId":1712,"briefTitle":1713,"status":758,"phases":1847,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":260,"conditions":1848,"interventions":1849},[84,85],[15],[1703,1719],{"trials":1851,"activeCount":95},[],{"trials":1853,"activeCount":95},[],{"trials":1855,"activeCount":95},[],{"intervention":1857,"totalTrials":91,"cells":1858},"tocilizumab",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1860,"activeCount":95},[],{"trials":1862,"activeCount":95},[],{"trials":1864,"activeCount":95},[1865],{"nctId":1866,"briefTitle":1867,"status":1688,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":665,"enrollment":95,"conditions":1870,"interventions":1872},"NCT02007239","Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)",[85],"2021-05",[1871],"Hemophagocytic Lymphohistiocytosis",[1857],{"trials":1874,"activeCount":95},[],{"trials":1876,"activeCount":95},[],{"trials":1878,"activeCount":95},[],{"intervention":1880,"totalTrials":91,"cells":1881},"Branched Chain Amino Acids",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1883,"activeCount":95},[],{"trials":1885,"activeCount":95},[],{"trials":1887,"activeCount":95},[1888],{"nctId":1889,"briefTitle":1890,"status":758,"phases":1891,"primaryCompletion":1892,"completion":1892,"start":1893,"enrollment":1894,"conditions":1895,"interventions":1897},"NCT01860404","BCAA Supplementation for Concussion",[85],"2023-01","2014-01",42,[1896],"Brain Concussion",[1880],{"trials":1899,"activeCount":95},[],{"trials":1901,"activeCount":95},[],{"trials":1903,"activeCount":95},[],{"intervention":1905,"totalTrials":91,"cells":1906},"Pantoprazole",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1908,"activeCount":95},[],{"trials":1910,"activeCount":95},[],{"trials":1912,"activeCount":95},[1913],{"nctId":1914,"briefTitle":1915,"status":758,"phases":1916,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":16,"conditions":1920,"interventions":1923},"NCT01848457","Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy",[85],"2016-01-04","2016-10-01","2013-04",[546,1921,1922],"Nephrotoxicity","Ototoxicity",[1905,1924],"High-dose methotrexate infusion duration",{"trials":1926,"activeCount":95},[],{"trials":1928,"activeCount":95},[],{"trials":1930,"activeCount":95},[],{"intervention":1924,"totalTrials":91,"cells":1932},{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1937,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1934,"activeCount":95},[],{"trials":1936,"activeCount":95},[],{"trials":1938,"activeCount":95},[1939],{"nctId":1914,"briefTitle":1915,"status":758,"phases":1940,"primaryCompletion":1917,"completion":1918,"start":1919,"enrollment":16,"conditions":1941,"interventions":1942},[85],[546,1921,1922],[1905,1924],{"trials":1944,"activeCount":95},[],{"trials":1946,"activeCount":95},[],{"trials":1948,"activeCount":95},[],{"intervention":1950,"totalTrials":91,"cells":1951},"Omeprazole 20mg",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1953,"activeCount":95},[],{"trials":1955,"activeCount":95},[],{"trials":1957,"activeCount":95},[1958],{"nctId":1959,"briefTitle":1960,"status":758,"phases":1961,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1967},"NCT03551691","Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)",[85],"2022-11-02","2018-08-07",19,[1966,15],"Pancreatic Insufficiency",[1950],{"trials":1969,"activeCount":95},[],{"trials":1971,"activeCount":95},[],{"trials":1973,"activeCount":95},[],{"intervention":1975,"totalTrials":91,"cells":1976},"Creon36™",{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1978,"activeCount":95},[],{"trials":1980,"activeCount":95},[],{"trials":1982,"activeCount":95},[1983],{"nctId":1984,"briefTitle":1985,"status":758,"phases":1986,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":1990,"interventions":1992},"NCT02849704","Fat Malabsorption in Chronic Pancreatitis",[85],"2017-11-01","2016-10-13",48,[1991],"Chronic Pancreatitis",[1975],{"trials":1994,"activeCount":95},[],{"trials":1996,"activeCount":95},[],{"trials":1998,"activeCount":95},[],{"intervention":2000,"totalTrials":91,"cells":2001},"Deferasirox and deferiprone",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2003,"activeCount":95},[],{"trials":2005,"activeCount":95},[],{"trials":2007,"activeCount":95},[2008],{"nctId":2009,"briefTitle":2010,"status":758,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":19,"conditions":2015,"interventions":2017},"NCT01709032","Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia",[84,85],"2015-08-01","2017-08-01","2012-09",[2016],"Thalassemia Major With Severe Transfusional Iron Overload",[2000],{"trials":2019,"activeCount":95},[],{"trials":2021,"activeCount":95},[],{"trials":2023,"activeCount":95},[],{"intervention":1453,"totalTrials":91,"cells":2025},{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2036,"PHASE4":2038,"NA":2040},{"trials":2027,"activeCount":95},[],{"trials":2029,"activeCount":95},[],{"trials":2031,"activeCount":95},[2032],{"nctId":1444,"briefTitle":1445,"status":758,"phases":2033,"primaryCompletion":665,"completion":1447,"start":1375,"enrollment":1448,"conditions":2034,"interventions":2035},[85],[1450,1451],[1435,1453],{"trials":2037,"activeCount":95},[],{"trials":2039,"activeCount":95},[],{"trials":2041,"activeCount":95},[],{"intervention":2043,"totalTrials":91,"cells":2044},"Pancreatic Enzyme",{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2046,"activeCount":95},[],{"trials":2048,"activeCount":95},[],{"trials":2050,"activeCount":95},[2051],{"nctId":2052,"briefTitle":2053,"status":758,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2060},"NCT03097029","Use of Pancreatic Enzymes in Short Bowel Syndrome",[85],"2019-02-01","2017-03-24",16,[2059],"Short Bowel Syndrome",[2043],{"trials":2062,"activeCount":95},[],{"trials":2064,"activeCount":95},[],{"trials":2066,"activeCount":95},[],{"intervention":2068,"totalTrials":91,"cells":2069},"Viaskin Milk 500 mcg",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2071,"activeCount":95},[],{"trials":2073,"activeCount":95},[],{"trials":2075,"activeCount":95},[2076],{"nctId":2077,"briefTitle":2078,"status":758,"phases":2079,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":206,"conditions":2083,"interventions":2085},"NCT02579876","Milk Patch for Eosinophilic Esophagitis",[85],"2017-12-20","2018-11-20","2015-10",[1233,2084],"Milk Allergy",[2068,2086],"Viaskin Placebo",{"trials":2088,"activeCount":95},[],{"trials":2090,"activeCount":95},[],{"trials":2092,"activeCount":95},[],{"intervention":2086,"totalTrials":91,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":95},[],{"trials":2098,"activeCount":95},[],{"trials":2100,"activeCount":95},[2101],{"nctId":2077,"briefTitle":2078,"status":758,"phases":2102,"primaryCompletion":2080,"completion":2081,"start":2082,"enrollment":206,"conditions":2103,"interventions":2104},[85],[1233,2084],[2068,2086],{"trials":2106,"activeCount":95},[],{"trials":2108,"activeCount":95},[],{"trials":2110,"activeCount":95},[],{"intervention":2112,"totalTrials":91,"cells":2113},"F-DOPA",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2115,"activeCount":95},[],{"trials":2117,"activeCount":95},[],{"trials":2119,"activeCount":95},[2120],{"nctId":2121,"briefTitle":2122,"status":758,"phases":2123,"primaryCompletion":1724,"completion":2124,"start":2125,"enrollment":2126,"conditions":2127,"interventions":2132},"NCT00674440","Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism",[85],"2009-01","2004-12",106,[2128,1693,2129,2130,2131],"Congenital Hyperinsulinism","Persistent Hyperinsulinemic Hypoglycemia of Infancy","CHI","PHHI",[2112],{"trials":2134,"activeCount":95},[],{"trials":2136,"activeCount":95},[],{"trials":2138,"activeCount":95},[],{"intervention":2140,"totalTrials":91,"cells":2141},"N-carbamylglutamate",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2143,"activeCount":95},[],{"trials":2145,"activeCount":95},[],{"trials":2147,"activeCount":95},[2148],{"nctId":2149,"briefTitle":2150,"status":1688,"phases":2151,"primaryCompletion":2152,"completion":2152,"start":2153,"enrollment":95,"conditions":2154,"interventions":2159},"NCT01341379","Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate",[85],"2012-08","2010-12",[2155,668,2156,2157,2158],"Urea Cycle Disorders, Inborn","Propionic Acidemia","Methylmalonic Acidemia","Carbamyl Phosphate Synthetase Deficiency",[2140],{"trials":2161,"activeCount":95},[],{"trials":2163,"activeCount":95},[],{"trials":2165,"activeCount":95},[],{"intervention":2167,"totalTrials":91,"cells":2168},"Progesterone",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2170,"activeCount":95},[],{"trials":2172,"activeCount":95},[],{"trials":2174,"activeCount":95},[2175],{"nctId":2176,"briefTitle":2177,"status":758,"phases":2178,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2182,"interventions":2188},"NCT02133573","Randomized Trial of Maternal Progesterone Therapy",[85],"2021-11","2014-07",102,[719,2183,2184,2185,2186,2187],"Periventricular Leucomalacia","Brain Development","Cardiac Surgery","Neurodevelopmental Disability","Fetal Neuroprotection",[2167,2189],"Vaginal lubricant",{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[],{"trials":2195,"activeCount":95},[],{"intervention":2189,"totalTrials":91,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2199,"activeCount":95},[],{"trials":2201,"activeCount":95},[],{"trials":2203,"activeCount":95},[2204],{"nctId":2176,"briefTitle":2177,"status":758,"phases":2205,"primaryCompletion":2179,"completion":2179,"start":2180,"enrollment":2181,"conditions":2206,"interventions":2207},[85],[719,2183,2184,2185,2186,2187],[2167,2189],{"trials":2209,"activeCount":95},[],{"trials":2211,"activeCount":95},[],{"trials":2213,"activeCount":95},[],{"intervention":2215,"totalTrials":91,"cells":2216},"Timolol 0.5% Gel Forming Solution",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2218,"activeCount":95},[],{"trials":2220,"activeCount":95},[],{"trials":2222,"activeCount":95},[2223],{"nctId":2224,"briefTitle":2225,"status":1688,"phases":2226,"primaryCompletion":1893,"completion":1893,"start":2227,"enrollment":95,"conditions":2228,"interventions":2230},"NCT01408056","Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)",[85],"2011-02",[2229],"Infantile Hemangiomas",[2215,2231],"Mupirocin 2% Ointment",{"trials":2233,"activeCount":95},[],{"trials":2235,"activeCount":95},[],{"trials":2237,"activeCount":95},[],{"intervention":2231,"totalTrials":91,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2241,"activeCount":95},[],{"trials":2243,"activeCount":95},[],{"trials":2245,"activeCount":95},[2246],{"nctId":2224,"briefTitle":2225,"status":1688,"phases":2247,"primaryCompletion":1893,"completion":1893,"start":2227,"enrollment":95,"conditions":2248,"interventions":2249},[85],[2229],[2215,2231],{"trials":2251,"activeCount":95},[],{"trials":2253,"activeCount":95},[],{"trials":2255,"activeCount":95},[],{"intervention":2257,"totalTrials":91,"cells":2258},"Metoclopramide",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2260,"activeCount":95},[],{"trials":2262,"activeCount":95},[],{"trials":2264,"activeCount":95},[2265],{"nctId":2266,"briefTitle":2267,"status":758,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2274},"NCT00355394","Treatment of Acute Migraine Headache in Children",[85],"2010-03","2006-08",31,[2273],"Migrainous Headache",[2257],{"trials":2276,"activeCount":95},[],{"trials":2278,"activeCount":95},[],{"trials":2280,"activeCount":95},[],{"intervention":2282,"totalTrials":91,"cells":2283},"18 F-DOPA",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2300,"PHASE4":2302,"NA":2304},{"trials":2285,"activeCount":95},[],{"trials":2287,"activeCount":95},[],{"trials":2289,"activeCount":95},[2290],{"nctId":2291,"briefTitle":2292,"status":758,"phases":2293,"primaryCompletion":1497,"completion":2294,"start":2124,"enrollment":2295,"conditions":2296,"interventions":2299},"NCT01468454","Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia",[85],"2018-02",130,[2297,2298],"Congenital Hyperinsulinism (CHI)","Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)",[2282],{"trials":2301,"activeCount":95},[],{"trials":2303,"activeCount":95},[],{"trials":2305,"activeCount":95},[],{"intervention":2307,"totalTrials":91,"cells":2308},"Celecoxib",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2310,"activeCount":95},[],{"trials":2312,"activeCount":95},[],{"trials":2314,"activeCount":95},[2315],{"nctId":2316,"briefTitle":2317,"status":758,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2325},"NCT02934191","Celecoxib After Tonsillectomy",[85],"2018-08-17","2019-01-31","2016-06",172,[2324],"Tonsillectomy",[2307,2326,2327],"Acetaminophen","Oxycodone",{"trials":2329,"activeCount":95},[],{"trials":2331,"activeCount":95},[],{"trials":2333,"activeCount":95},[],{"intervention":2326,"totalTrials":91,"cells":2335},{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2337,"activeCount":95},[],{"trials":2339,"activeCount":95},[],{"trials":2341,"activeCount":95},[2342],{"nctId":2316,"briefTitle":2317,"status":758,"phases":2343,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":2322,"conditions":2344,"interventions":2345},[85],[2324],[2307,2326,2327],{"trials":2347,"activeCount":95},[],{"trials":2349,"activeCount":95},[],{"trials":2351,"activeCount":95},[],{"intervention":2327,"totalTrials":91,"cells":2353},{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2364,"PHASE4":2366,"NA":2368},{"trials":2355,"activeCount":95},[],{"trials":2357,"activeCount":95},[],{"trials":2359,"activeCount":95},[2360],{"nctId":2316,"briefTitle":2317,"status":758,"phases":2361,"primaryCompletion":2319,"completion":2320,"start":2321,"enrollment":2322,"conditions":2362,"interventions":2363},[85],[2324],[2307,2326,2327],{"trials":2365,"activeCount":95},[],{"trials":2367,"activeCount":95},[],{"trials":2369,"activeCount":95},[],{"intervention":2371,"totalTrials":91,"cells":2372},"Vancomycin",{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2374,"activeCount":95},[],{"trials":2376,"activeCount":95},[],{"trials":2378,"activeCount":95},[2379],{"nctId":2380,"briefTitle":2381,"status":758,"phases":2382,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":1663,"conditions":2385,"interventions":2387},"NCT03476317","Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease",[85],"2020-12-31","2018-07-12",[2386],"Crohn Disease",[2371,2388,2389,2390,2391],"Neomycin","Ciprofloxacin","Polyethylene Glycol 3350","Fluconazole",{"trials":2393,"activeCount":95},[],{"trials":2395,"activeCount":95},[],{"trials":2397,"activeCount":95},[],{"intervention":2388,"totalTrials":91,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":95},[],{"trials":2403,"activeCount":95},[],{"trials":2405,"activeCount":95},[2406],{"nctId":2380,"briefTitle":2381,"status":758,"phases":2407,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":1663,"conditions":2408,"interventions":2409},[85],[2386],[2371,2388,2389,2390,2391],{"trials":2411,"activeCount":95},[],{"trials":2413,"activeCount":95},[],{"trials":2415,"activeCount":95},[],{"intervention":2389,"totalTrials":91,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":95},[],{"trials":2421,"activeCount":95},[],{"trials":2423,"activeCount":95},[2424],{"nctId":2380,"briefTitle":2381,"status":758,"phases":2425,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":1663,"conditions":2426,"interventions":2427},[85],[2386],[2371,2388,2389,2390,2391],{"trials":2429,"activeCount":95},[],{"trials":2431,"activeCount":95},[],{"trials":2433,"activeCount":95},[],{"intervention":2390,"totalTrials":91,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":95},[],{"trials":2439,"activeCount":95},[],{"trials":2441,"activeCount":95},[2442],{"nctId":2380,"briefTitle":2381,"status":758,"phases":2443,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":1663,"conditions":2444,"interventions":2445},[85],[2386],[2371,2388,2389,2390,2391],{"trials":2447,"activeCount":95},[],{"trials":2449,"activeCount":95},[],{"trials":2451,"activeCount":95},[],{"intervention":2391,"totalTrials":91,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":95},[],{"trials":2457,"activeCount":95},[],{"trials":2459,"activeCount":95},[2460],{"nctId":2380,"briefTitle":2381,"status":758,"phases":2461,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":1663,"conditions":2462,"interventions":2463},[85],[2386],[2371,2388,2389,2390,2391],{"trials":2465,"activeCount":95},[],{"trials":2467,"activeCount":95},[],{"trials":2469,"activeCount":95},[],{"intervention":1270,"totalTrials":91,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":95},[],{"trials":2475,"activeCount":95},[],{"trials":2477,"activeCount":95},[2478],{"nctId":1261,"briefTitle":1262,"status":758,"phases":2479,"primaryCompletion":1264,"completion":1265,"start":871,"enrollment":1266,"conditions":2480,"interventions":2481},[85],[1268],[1270,1238],{"trials":2483,"activeCount":95},[],{"trials":2485,"activeCount":95},[],{"trials":2487,"activeCount":95},[],{"intervention":2489,"totalTrials":91,"cells":2490},"Interferon Gamma-1b",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2492,"activeCount":95},[],{"trials":2494,"activeCount":95},[],{"trials":2496,"activeCount":95},[2497],{"nctId":2498,"briefTitle":2499,"status":758,"phases":2500,"primaryCompletion":2501,"completion":2502,"start":2503,"enrollment":260,"conditions":2504,"interventions":2505},"NCT01965327","Interferon Gamma-1b in Friedreich Ataxia (FRDA)",[85],"2014-03","2014-10","2013-08",[1806],[2489],{"trials":2507,"activeCount":95},[],{"trials":2509,"activeCount":95},[],{"trials":2511,"activeCount":95},[],{"intervention":2513,"totalTrials":91,"cells":2514},"Hydroxyurea",{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2530,"PHASE4":2532,"NA":2534},{"trials":2516,"activeCount":95},[],{"trials":2518,"activeCount":95},[],{"trials":2520,"activeCount":95},[2521],{"nctId":2522,"briefTitle":2523,"status":1688,"phases":2524,"primaryCompletion":896,"completion":896,"start":2525,"enrollment":95,"conditions":2526,"interventions":2529},"NCT00978146","Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors",[85],"2009-10",[2527,2528],"Desmoid Tumors","Fibromatosis",[2513],{"trials":2531,"activeCount":95},[],{"trials":2533,"activeCount":95},[],{"trials":2535,"activeCount":95},[],{"intervention":2537,"totalTrials":91,"cells":2538},"Sirolimus and Methotrexate",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2554,"PHASE4":2556,"NA":2558},{"trials":2540,"activeCount":95},[],{"trials":2542,"activeCount":95},[],{"trials":2544,"activeCount":95},[2545],{"nctId":2546,"briefTitle":2547,"status":758,"phases":2548,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":2551,"conditions":2552,"interventions":2553},"NCT01162551","Trial of Sirolimus and Methotrexate in Relapsed\u002FRefractory Lymphoblastic Leukemia and Lymphoma",[85],"2017-02","2010-05",5,[23,33,1665],[2537],{"trials":2555,"activeCount":95},[],{"trials":2557,"activeCount":95},[],{"trials":2559,"activeCount":95},[],{"intervention":2561,"totalTrials":91,"cells":2562},"Topical Lidocaine 4% Cream",{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2564,"activeCount":95},[],{"trials":2566,"activeCount":95},[],{"trials":2568,"activeCount":95},[2569],{"nctId":2570,"briefTitle":2571,"status":758,"phases":2572,"primaryCompletion":2573,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2578},"NCT01394250","Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief",[85],"2013-09","2011-06",240,[899,2577],"Anxiety",[2561],{"trials":2580,"activeCount":95},[],{"trials":2582,"activeCount":95},[],{"trials":2584,"activeCount":95},[],{"intervention":2586,"totalTrials":91,"cells":2587},"Sildenafil",{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2589,"activeCount":95},[],{"trials":2591,"activeCount":95},[],{"trials":2593,"activeCount":95},[2594],{"nctId":2595,"briefTitle":2596,"status":758,"phases":2597,"primaryCompletion":1660,"completion":2598,"start":760,"enrollment":717,"conditions":2599,"interventions":2602},"NCT00507819","Sildenafil After the Fontan Operation",[85],"2009-07",[2600,2601],"Hypoplastic Left Heart Syndrome","Tricuspid Atresia",[2586],{"trials":2604,"activeCount":95},[],{"trials":2606,"activeCount":95},[],{"trials":2608,"activeCount":95},[],{"intervention":2610,"totalTrials":91,"cells":2611},"Vitamin E",{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2613,"activeCount":95},[],{"trials":2615,"activeCount":95},[],{"trials":2617,"activeCount":95},[2618],{"nctId":2619,"briefTitle":2620,"status":1688,"phases":2621,"primaryCompletion":2622,"completion":2622,"start":2623,"enrollment":95,"conditions":2624,"interventions":2626},"NCT04984798","Vitamin E Efficacy in HI\u002FHA",[85],"2023-03","2022-11",[2625],"Hyperinsulinism-Hyperammonemia Syndrome",[2610],{"trials":2628,"activeCount":95},[],{"trials":2630,"activeCount":95},[],{"trials":2632,"activeCount":95},[],{"intervention":2634,"totalTrials":91,"cells":2635},"Cholecalciferol",{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2637,"activeCount":95},[],{"trials":2639,"activeCount":95},[],{"trials":2641,"activeCount":95},[2642],{"nctId":2643,"briefTitle":2644,"status":758,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2652},"NCT01092338","Vitamin D Dose Finding Study",[85],"2011-01","2010-01",44,[2650,2651],"HIV Infections","AIDS",[2634],{"trials":2654,"activeCount":95},[],{"trials":2656,"activeCount":95},[],{"trials":2658,"activeCount":95},[],{"intervention":1728,"totalTrials":91,"cells":2660},{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2662,"activeCount":95},[],{"trials":2664,"activeCount":95},[],{"trials":2666,"activeCount":95},[2667],{"nctId":1721,"briefTitle":1722,"status":713,"phases":2668,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":19,"conditions":2669,"interventions":2670},[84,85],[15],[1703,1728],{"trials":2672,"activeCount":95},[],{"trials":2674,"activeCount":95},[],{"trials":2676,"activeCount":95},[],{"intervention":2678,"totalTrials":91,"cells":2679},"Pimecrolimus 1% Cream",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2695,"PHASE4":2697,"NA":2699},{"trials":2681,"activeCount":95},[],{"trials":2683,"activeCount":95},[],{"trials":2685,"activeCount":95},[2686],{"nctId":2687,"briefTitle":2688,"status":758,"phases":2689,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":985,"conditions":2692,"interventions":2694},"NCT00208026","Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome",[84,85],"2008-03","2005-09",[2693],"Netherton Syndrome",[2678],{"trials":2696,"activeCount":95},[],{"trials":2698,"activeCount":95},[],{"trials":2700,"activeCount":95},[],{"intervention":2702,"totalTrials":91,"cells":2703},"Tenofovir",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2705,"activeCount":95},[],{"trials":2707,"activeCount":95},[],{"trials":2709,"activeCount":95},[2710],{"nctId":2711,"briefTitle":2712,"status":1688,"phases":2713,"primaryCompletion":2714,"completion":2714,"start":2715,"enrollment":95,"conditions":2716,"interventions":2718},"NCT03304717","Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome",[84,85],"2029-12","2025-12",[2717],"Aicardi Goutières Syndrome",[2702],{"trials":2720,"activeCount":95},[],{"trials":2722,"activeCount":95},[],{"trials":2724,"activeCount":95},[],{"intervention":2726,"totalTrials":91,"cells":2727},"LS11",{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2741,"PHASE3":2743,"PHASE4":2745,"NA":2747},{"trials":2729,"activeCount":95},[],{"trials":2731,"activeCount":95},[2732],{"nctId":2733,"briefTitle":2734,"status":713,"phases":2735,"primaryCompletion":2736,"completion":2736,"start":2737,"enrollment":27,"conditions":2738,"interventions":2740},"NCT00716469","Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas",[84],"2012-07","2008-07",[2739],"Neurofibroma",[2726],{"trials":2742,"activeCount":95},[],{"trials":2744,"activeCount":95},[],{"trials":2746,"activeCount":95},[],{"trials":2748,"activeCount":95},[],{"intervention":2750,"totalTrials":91,"cells":2751},"paclitaxel",{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2766,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2753,"activeCount":95},[],{"trials":2755,"activeCount":95},[2756],{"nctId":2757,"briefTitle":2758,"status":713,"phases":2759,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":2762,"conditions":2763,"interventions":2765},"NCT00031577","Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma",[84],"2006-09","1999-08",11,[2764],"Brain and Central Nervous System Tumors",[2750],{"trials":2767,"activeCount":95},[],{"trials":2769,"activeCount":95},[],{"trials":2771,"activeCount":95},[],{"trials":2773,"activeCount":95},[],{"intervention":2775,"totalTrials":91,"cells":2776},"Perfluorooctyl Bromide",{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2778,"activeCount":95},[],{"trials":2780,"activeCount":95},[2781],{"nctId":2782,"briefTitle":2783,"status":758,"phases":2784,"primaryCompletion":2785,"completion":2785,"start":2786,"enrollment":2057,"conditions":2787,"interventions":2788},"NCT03041740","Fluid Filled Lung Oxygenation Assistance Trial",[84],"2019-06-10","2017-06-27",[26],[2775],{"trials":2790,"activeCount":95},[],{"trials":2792,"activeCount":95},[],{"trials":2794,"activeCount":95},[],{"trials":2796,"activeCount":95},[],{"intervention":2798,"totalTrials":91,"cells":2799},"D+ RH genotype matched red cell units for transfusion",{"EARLY_PHASE1":2800,"PHASE1":2812,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2801,"activeCount":95},[2802],{"nctId":2803,"briefTitle":2804,"status":758,"phases":2805,"primaryCompletion":2806,"completion":2807,"start":2808,"enrollment":2551,"conditions":2809,"interventions":2811},"NCT04156906","RHD Genotype Matched Red Cells for Anti-D",[83],"2024-03-04","2024-10-04","2020-07-08",[987,2810],"Anti-D Antibodies",[2798],{"trials":2813,"activeCount":95},[],{"trials":2815,"activeCount":95},[],{"trials":2817,"activeCount":95},[],{"trials":2819,"activeCount":95},[],{"trials":2821,"activeCount":95},[],{"intervention":2823,"totalTrials":91,"cells":2824},"Milk Protein Powder",{"EARLY_PHASE1":2825,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2826,"activeCount":95},[2827],{"nctId":2828,"briefTitle":2829,"status":758,"phases":2830,"primaryCompletion":665,"completion":665,"start":2831,"enrollment":11,"conditions":2832,"interventions":2834},"NCT01162473","Milk Oral Immunotherapy in Children to Treat Food Allergy",[83],"2010-06",[2833],"Milk Hypersensitivity",[2823],{"trials":2836,"activeCount":95},[],{"trials":2838,"activeCount":95},[],{"trials":2840,"activeCount":95},[],{"trials":2842,"activeCount":95},[],{"trials":2844,"activeCount":95},[],{"intervention":2846,"totalTrials":91,"cells":2847},"Rosuvastatin",{"EARLY_PHASE1":2848,"PHASE1":2858,"PHASE2":2860,"PHASE3":2862,"PHASE4":2864,"NA":2866},{"trials":2849,"activeCount":95},[2850],{"nctId":2851,"briefTitle":2852,"status":758,"phases":2853,"primaryCompletion":2854,"completion":2854,"start":2855,"enrollment":260,"conditions":2856,"interventions":2857},"NCT02705547","Rosuvastatin (Crestor) in Friedreich Ataxia",[83],"2017-08-04","2016-05",[1806],[2846],{"trials":2859,"activeCount":95},[],{"trials":2861,"activeCount":95},[],{"trials":2863,"activeCount":95},[],{"trials":2865,"activeCount":95},[],{"trials":2867,"activeCount":95},[],{"intervention":2869,"totalTrials":91,"cells":2870},"Methylprednisolone",{"EARLY_PHASE1":2871,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2872,"activeCount":95},[2873],{"nctId":2874,"briefTitle":2875,"status":758,"phases":2876,"primaryCompletion":2877,"completion":2878,"start":2879,"enrollment":2762,"conditions":2880,"interventions":2881},"NCT02424435","Methylprednisolone Treatment of Friedreich Ataxia",[83],"2017-12","2018-04","2015-06",[1806],[2869],{"trials":2883,"activeCount":95},[],{"trials":2885,"activeCount":95},[],{"trials":2887,"activeCount":95},[],{"trials":2889,"activeCount":95},[],{"trials":2891,"activeCount":95},[],{"intervention":2893,"totalTrials":985,"cells":2894},"Bupivacaine",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2912,"NA":2925},{"trials":2896,"activeCount":95},[],{"trials":2898,"activeCount":95},[],{"trials":2900,"activeCount":95},[],{"trials":2902,"activeCount":95},[2903],{"nctId":2904,"briefTitle":2905,"status":713,"phases":2906,"primaryCompletion":2907,"completion":2907,"start":2501,"enrollment":91,"conditions":2908,"interventions":2910},"NCT02075411","Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair",[86],"2015-02",[2909],"Injury of Anterior Cruciate Ligament",[2911,2911],"bupivacaine",{"trials":2913,"activeCount":95},[2914],{"nctId":2915,"briefTitle":2916,"status":713,"phases":2917,"primaryCompletion":2918,"completion":1660,"start":2919,"enrollment":2057,"conditions":2920,"interventions":2924},"NCT00314457","Efficacy Study of Continuous Intraarticular Infusion in Patients Undergoing Arthroscopic Knee and Shoulder Operations",[87],"2007-02","2005-08",[2921,2922,2923],"ACL Repair","Meniscectomy","Bankart Repair",[2893],{"trials":2926,"activeCount":95},[2927],{"nctId":2928,"briefTitle":2929,"status":758,"phases":2930,"primaryCompletion":2931,"completion":1120,"start":1165,"enrollment":1641,"conditions":2932,"interventions":2934},"NCT00578136","Analgesic Efficacy After Umbilical Hernia Repair in Children",[88],"2009-12",[2933],"Umbilical Hernia",[2893],{"intervention":2936,"totalTrials":704,"cells":2937},"Infasurf",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2946,"NA":2948},{"trials":2939,"activeCount":95},[],{"trials":2941,"activeCount":95},[],{"trials":2943,"activeCount":95},[],{"trials":2945,"activeCount":95},[],{"trials":2947,"activeCount":95},[],{"trials":2949,"activeCount":95},[2950,2959],{"nctId":2951,"briefTitle":2952,"status":758,"phases":2953,"completion":1037,"start":2954,"enrollment":2955,"conditions":2956,"interventions":2958},"NCT00208039","Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates",[88],"2004-09",89,[2957,26],"Respiratory Distress Syndrome",[2936],{"nctId":2960,"briefTitle":2961,"status":758,"phases":2962,"completion":2963,"start":2964,"enrollment":2762,"conditions":2965,"interventions":2966},"NCT00165074","Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation",[88],"2007-06","2003-06",[2957],[2936],{"intervention":2968,"totalTrials":704,"cells":2969},"insulin-like growth factor I",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2971,"activeCount":95},[],{"trials":2973,"activeCount":95},[],{"trials":2975,"activeCount":95},[2976],{"nctId":2977,"briefTitle":2978,"status":758,"phases":2979,"completion":2980,"start":2981,"enrollment":2057,"conditions":2982,"interventions":2983},"NCT00004700","Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism",[85],"1999-01","1995-08",[1693],[2968],{"trials":2985,"activeCount":95},[],{"trials":2987,"activeCount":95},[],{"trials":2989,"activeCount":95},[2990],{"nctId":2991,"briefTitle":2992,"status":758,"phases":2993,"completion":2980,"start":2981,"enrollment":24,"conditions":2994,"interventions":2995},"NCT00004699","Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism",[88],[1693],[2968],{"intervention":2997,"totalTrials":91,"cells":2998},"Repaglinide and Insulin",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":3000,"activeCount":95},[],{"trials":3002,"activeCount":95},[],{"trials":3004,"activeCount":95},[],{"trials":3006,"activeCount":95},[],{"trials":3008,"activeCount":95},[],{"trials":3010,"activeCount":95},[3011],{"nctId":3012,"briefTitle":3013,"status":1688,"phases":3014,"completion":3015,"start":1715,"enrollment":95,"conditions":3016,"interventions":3018},"NCT00231192","Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes",[88],"2007-08",[3017],"Diabetes",[2997],{"intervention":3020,"totalTrials":91,"cells":3021},"Orkambi",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":95},[],{"trials":3025,"activeCount":95},[],{"trials":3027,"activeCount":95},[],{"trials":3029,"activeCount":95},[],{"trials":3031,"activeCount":95},[],{"trials":3033,"activeCount":95},[3034],{"nctId":3035,"briefTitle":3036,"status":758,"phases":3037,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":717,"conditions":3040,"interventions":3041},"NCT03795363","Orkambi Treatment in 2 to 5 Year Old Children With CF",[],"2021-06-16","2019-04-10",[15],[3020],{"intervention":3043,"totalTrials":91,"cells":3044},"Albuterol Sulfate",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3055},{"trials":3046,"activeCount":95},[],{"trials":3048,"activeCount":95},[],{"trials":3050,"activeCount":95},[],{"trials":3052,"activeCount":95},[],{"trials":3054,"activeCount":95},[],{"trials":3056,"activeCount":95},[3057],{"nctId":3058,"briefTitle":3059,"status":758,"phases":3060,"primaryCompletion":3061,"completion":3061,"start":3062,"enrollment":395,"conditions":3063,"interventions":3065},"NCT02766673","Aerosolized Albuterol Use in Severe BPD",[88],"2018-06","2016-08",[3064],"Severe Bronchopulmonary Dysplasia",[3043,3066],"Sterile Saline",{"intervention":3066,"totalTrials":91,"cells":3068},{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3070,"activeCount":95},[],{"trials":3072,"activeCount":95},[],{"trials":3074,"activeCount":95},[],{"trials":3076,"activeCount":95},[],{"trials":3078,"activeCount":95},[],{"trials":3080,"activeCount":95},[3081],{"nctId":3058,"briefTitle":3059,"status":758,"phases":3082,"primaryCompletion":3061,"completion":3061,"start":3062,"enrollment":395,"conditions":3083,"interventions":3084},[88],[3064],[3043,3066],{"intervention":3086,"totalTrials":91,"cells":3087},"Milrinone Lactate",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3089,"activeCount":95},[],{"trials":3091,"activeCount":95},[],{"trials":3093,"activeCount":95},[],{"trials":3095,"activeCount":95},[],{"trials":3097,"activeCount":95},[],{"trials":3099,"activeCount":95},[3100],{"nctId":3101,"briefTitle":3102,"status":713,"phases":3103,"primaryCompletion":3104,"completion":3105,"start":2831,"enrollment":260,"conditions":3106,"interventions":3108},"NCT01088997","Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn",[88],"2013-02","2015-05",[3107],"Persistent Fetal Circulation Syndrome",[3086],{"intervention":3110,"totalTrials":91,"cells":3111},"Ivacaftor",{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3113,"activeCount":95},[],{"trials":3115,"activeCount":95},[],{"trials":3117,"activeCount":95},[],{"trials":3119,"activeCount":95},[],{"trials":3121,"activeCount":95},[],{"trials":3123,"activeCount":95},[3124],{"nctId":3125,"briefTitle":3126,"status":758,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":3130,"conditions":3131,"interventions":3132},"NCT03783286","Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects",[],"2021-12-30","2019-02-06",15,[15],[3110],{"intervention":3134,"totalTrials":91,"cells":3135},"Proparacaine Hydrochloride Ophthalmic Solution",{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3137,"activeCount":95},[],{"trials":3139,"activeCount":95},[],{"trials":3141,"activeCount":95},[],{"trials":3143,"activeCount":95},[],{"trials":3145,"activeCount":95},[],{"trials":3147,"activeCount":95},[3148],{"nctId":3149,"briefTitle":3150,"status":713,"phases":3151,"primaryCompletion":1264,"completion":1264,"start":2153,"enrollment":2551,"conditions":3152,"interventions":3154},"NCT01266824","Proparacaine and Mydriatic Eye Drops",[88],[899,3153],"Retinopathy of Prematurity",[3134],{"intervention":3156,"totalTrials":91,"cells":3157},"polyethylene glycol powder",{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3159,"activeCount":95},[],{"trials":3161,"activeCount":95},[],{"trials":3163,"activeCount":95},[],{"trials":3165,"activeCount":95},[],{"trials":3167,"activeCount":95},[],{"trials":3169,"activeCount":95},[3170],{"nctId":3171,"briefTitle":3172,"status":758,"phases":3173,"primaryCompletion":1893,"completion":1893,"start":3174,"enrollment":3175,"conditions":3176,"interventions":3178},"NCT01626040","Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children",[],"2012-06",178,[3177],"Water-Electrolyte Imbalance",[3156],{"intervention":3180,"totalTrials":91,"cells":3181},"Intrathecal Morphine",{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3188,"PHASE4":3190,"NA":3192},{"trials":3183,"activeCount":95},[],{"trials":3185,"activeCount":95},[],{"trials":3187,"activeCount":95},[],{"trials":3189,"activeCount":95},[],{"trials":3191,"activeCount":95},[],{"trials":3193,"activeCount":95},[3194],{"nctId":3195,"briefTitle":3196,"status":758,"phases":3197,"primaryCompletion":1660,"completion":1660,"start":3015,"enrollment":3198,"conditions":3199,"interventions":3201},"NCT00596609","Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials",[],36,[3200],"Trauma, Nervous System",[3180],{"intervention":3203,"totalTrials":91,"cells":3204},"oral melatonin",{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3206,"activeCount":95},[],{"trials":3208,"activeCount":95},[],{"trials":3210,"activeCount":95},[],{"trials":3212,"activeCount":95},[],{"trials":3214,"activeCount":95},[],{"trials":3216,"activeCount":95},[3217],{"nctId":3218,"briefTitle":3219,"status":758,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":3222,"enrollment":9,"conditions":3223,"interventions":3226},"NCT03826563","Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms",[88],"2023-04-07","2019-01-18",[3224,3225],"Psychosis","Sleep",[3203],{"intervention":3228,"totalTrials":91,"cells":3229},"Sapropterin",{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3236,"PHASE4":3238,"NA":3240},{"trials":3231,"activeCount":95},[],{"trials":3233,"activeCount":95},[],{"trials":3235,"activeCount":95},[],{"trials":3237,"activeCount":95},[],{"trials":3239,"activeCount":95},[],{"trials":3241,"activeCount":95},[3242],{"nctId":3243,"briefTitle":3244,"status":758,"phases":3245,"primaryCompletion":1499,"completion":3246,"start":2269,"enrollment":3247,"conditions":3248,"interventions":3250},"NCT00986973","Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy",[88],"2011-09",6,[3249],"Phenylketonuria",[3228],{"intervention":3252,"totalTrials":91,"cells":3253},"PEG 3350",{"EARLY_PHASE1":3254,"PHASE1":3256,"PHASE2":3258,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3255,"activeCount":95},[],{"trials":3257,"activeCount":95},[],{"trials":3259,"activeCount":95},[],{"trials":3261,"activeCount":95},[],{"trials":3263,"activeCount":95},[],{"trials":3265,"activeCount":95},[3266],{"nctId":3267,"briefTitle":3268,"status":758,"phases":3269,"primaryCompletion":3270,"completion":3270,"start":3271,"enrollment":3272,"conditions":3273,"interventions":3276},"NCT05424757","Polyethylene Glycol Safety in Children",[],"2025-08-09","2022-09-30",158,[3274,3275],"Polyethylene Glycols","Children, Only",[3252],{"intervention":3278,"totalTrials":91,"cells":3279},"Broad-spectrum antibiotics",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3281,"activeCount":95},[],{"trials":3283,"activeCount":95},[],{"trials":3285,"activeCount":95},[],{"trials":3287,"activeCount":95},[],{"trials":3289,"activeCount":95},[],{"trials":3291,"activeCount":95},[3292],{"nctId":3293,"briefTitle":3294,"status":758,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":1893,"enrollment":3297,"conditions":3298,"interventions":3302},"NCT02297815","Comparative Effectiveness of Antibiotics for Respiratory Infections",[],"2016-04",2472,[3299,3300,3301],"Acute Otitis Media","Acute Sinusitis","Group A Streptococcal Pharyngitis",[3278,3303],"Narrow-spectrum antibiotics",{"intervention":3303,"totalTrials":91,"cells":3305},{"EARLY_PHASE1":3306,"PHASE1":3308,"PHASE2":3310,"PHASE3":3312,"PHASE4":3314,"NA":3316},{"trials":3307,"activeCount":95},[],{"trials":3309,"activeCount":95},[],{"trials":3311,"activeCount":95},[],{"trials":3313,"activeCount":95},[],{"trials":3315,"activeCount":95},[],{"trials":3317,"activeCount":95},[3318],{"nctId":3293,"briefTitle":3294,"status":758,"phases":3319,"primaryCompletion":3296,"completion":3296,"start":1893,"enrollment":3297,"conditions":3320,"interventions":3321},[],[3299,3300,3301],[3278,3303],{"intervention":3323,"totalTrials":91,"cells":3324},"Omegaven",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3333,"NA":3335},{"trials":3326,"activeCount":95},[],{"trials":3328,"activeCount":95},[],{"trials":3330,"activeCount":95},[],{"trials":3332,"activeCount":95},[],{"trials":3334,"activeCount":95},[],{"trials":3336,"activeCount":95},[3337],{"nctId":3338,"briefTitle":3339,"status":3340,"phases":3341,"conditions":3342,"interventions":3344},"NCT01297933","Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease","APPROVED_FOR_MARKETING",[],[3343,2059],"Cholestasis",[3323],{"intervention":3346,"totalTrials":91,"cells":3347},"18F-DOPA",{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3354,"PHASE4":3356,"NA":3358},{"trials":3349,"activeCount":95},[],{"trials":3351,"activeCount":95},[],{"trials":3353,"activeCount":95},[],{"trials":3355,"activeCount":95},[],{"trials":3357,"activeCount":95},[],{"trials":3359,"activeCount":95},[3360],{"nctId":3361,"briefTitle":3362,"status":3363,"phases":3364,"conditions":3365,"interventions":3368},"NCT01916148","18F-L-Fluoro-DOPA PET\u002FCT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia","AVAILABLE",[],[2297,3366,3367],"Beckwith-Wiedemann Syndrome","Insulinoma",[3346],{"intervention":3370,"totalTrials":91,"cells":3371},"Levothyroxine",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3378,"PHASE4":3380,"NA":3382},{"trials":3373,"activeCount":95},[],{"trials":3375,"activeCount":95},[],{"trials":3377,"activeCount":95},[],{"trials":3379,"activeCount":95},[],{"trials":3381,"activeCount":95},[],{"trials":3383,"activeCount":95},[3384],{"nctId":3385,"briefTitle":3386,"status":758,"phases":3387,"primaryCompletion":3388,"completion":3388,"start":3389,"enrollment":260,"conditions":3390,"interventions":3393},"NCT01832753","Treatment Trial of Subclinical Hypothyroidism in Down Syndrome",[88],"2017-10-18","2013-01",[3391,3392],"Down Syndrome","Subclinical Hypothyroidism",[3370],{"intervention":3395,"totalTrials":91,"cells":3396},"deferiprone",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3398,"activeCount":95},[],{"trials":3400,"activeCount":95},[],{"trials":3402,"activeCount":95},[],{"trials":3404,"activeCount":95},[],{"trials":3406,"activeCount":95},[],{"trials":3408,"activeCount":95},[3409],{"nctId":3410,"briefTitle":3411,"status":3340,"phases":3412,"start":3413,"conditions":3414,"interventions":3416},"NCT00293098","Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease",[],"2006-03",[3415],"Iron Overload",[3395]]